Biosynex

Equities

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris Other stock markets 10:55:29 2024-07-16 am EDT			5-day change	1st Jan Change
3.35 ^EUR	-3.04%		-4.01%	-59.88%

May. 28	Biosynex: obtains CE markings under the new IVDR regulations	CF
May. 13	Biosynex: Oren Bitton appointed Chief Operating Officer	CF

Biosynex extends partnership with Credo Diagnostics

January 16, 2023 at 01:48 am EST

Biosynex announces the extension of its partnership with Singapore-based Credo Diagnostics Biomedical, by signing an exclusive agreement for the distribution of VitaPCR systems for an extended territory including the UK.

In addition, under the new agreement, Credo Diagnostics will launch a next-generation rapid PCR platform, VitaSIRO solo, based on microfluidics that simplifies the entire procedure.

At the start of the Covid-19 health crisis in March 2020, the French rapid diagnostic test company and Credo Diagnostics had agreed to distribute VitaPCR systems for France, Belgium, Switzerland and Luxembourg.

Copyright (c) 2023 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Latest news about Biosynex

Biosynex: obtains CE markings under the new IVDR regulations	May. 28	CF
Biosynex: Oren Bitton appointed Chief Operating Officer	May. 13	CF
Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 30	CI
Biosynex: agreement for ProciseDx in North America	Apr. 29	CF
Biosynex: merger with Theradiag completed	Dec. 18	CF
Biosynex SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-29	CI
Biosynex: acquisition of Qualigen in the United States	23-07-21	CF
Biosynex Unit to Acquire US-based Biotech Qualigen	23-07-21	MT
Biosynex SA acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.	23-06-12	CI
Biosynex SA signed an agreement to acquire 57.33% interest in ProciseDx Inc. from NestlÃ© HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.	23-06-11	CI
Biosynex: acquires Innoxa's eye care business	23-06-08	CF
Biosynex SA acquired Eye Care activity from LABORATOIRES INNOXA.	23-06-07	CI
Biosynex SA completed the acquisition of Chembio Diagnostics, Inc. from Perceptive Advisors LLC and others.	23-04-26	CI
Global markets live: EssilorLuxottica, AT&T, Tesla, Credit Suisse, Sony...	23-04-21
Biosynex: share price falls as results deteriorate	23-04-21	CF
Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-20	CI
Chembio Diagnostics Tender Offer Expiration Extended by Biosynex	23-04-13	MT
Biosynex: takeover bid extended for Chembio Diagnostics	23-03-29	CF
Biosynex Unit Extends Expiration Time of Tender Offer for Chembio Diagnostics Shares; Stock Rises	23-03-29	MT
Biosynex: hot water bottles withdrawn from sale	23-03-09	CF
Chembio Diagnostics Agrees to $17.2 Million Takeover by Biosynex; Shares Rise Pre-Bell	23-02-01	MT
Biosynex SA completed the acquisition of additional 46.52% stake in Theradiag SA for €21.6 million.	23-01-30	CI
Biosynex SA entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. for $17.2 million.	23-01-30	CI
Eurobio Scientific: 2022 sales down 17%.	23-01-24	CF
Biosynex: 49% decline in annual sales	23-01-19	CF

Chart Biosynex

Duration

Period

More charts

Company Profile

Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas: - manufacturing of diagnosis tests for own account; - sale of diagnosis tests supplied by other manufacturers of semi-finished products; - research and development services for third party; - sale of licenses; - sale of biological reagents. At the end of 2023, the group had one production site located in France. France accounts for 56.5% of net sales.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOSYNEX	-59.88%	40.58M
BIOMÉRIEUX	-6.66%	12.28B
LANTHEUS HOLDINGS, INC.	+90.81%	8.54B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-22.14%	6.58B
DIASORIN S.P.A.	+8.86%	5.77B
AUTOBIO DIAGNOSTICS CO., LTD.	-23.82%	3.48B
ANDON HEALTH CO., LTD.	+5.12%	2.54B
MYRIAD GENETICS, INC.	+43.10%	2.41B
VITROLIFE AB	-7.24%	2.3B
10X GENOMICS, INC.	-64.26%	2.07B

Diagnostic & Testing Substances